-
-
-
-
-
-
-
RBC Capital Reiterates Outperform Rating on Regenxbio Inc. (RGNX)
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) option implied volatility flat
-
-
-
-
-
-
-
Raymond James Stays Sidelined on Sarepta (SRPT) Citing 'heavily eclipsed market opportunity' and 'binary risk heading into EMBARK'
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) option implied volatility into PDUFA
-
-
-
-
-
-
-
Sarepta (SRPT) sinks 20% as surprise FDA AdComm for SRP-9001 adds risk
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) Buy Rating Reiterated At Needham After Exondys Sales Guidance Is Maintained
-
-
-
-
-
-
-
Sarepta Therapeutics Announces Second Quarter 2016 Financial Results and Recent Corporate Developments
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

